KRAS and non-small cell lung carcinoma: Based on these results, Sotorasib was granted breakthrough designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with KRAS G12C mt locally advanced or metastatic NSCLC who have received at least one prior systemic therapy, becoming the first targeted therapy approved for advanced NSCLC KRAS G12C mt (50).